Immunological aspects of approved MS therapeutics
Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …
to disability in young adults. The outcome of the disease is unpredictable, and over time …
Advances in oral immunomodulating therapies in relapsing multiple sclerosis
Background Oral treatment options for disease-modifying therapy in relapsing multiple
sclerosis have substantially increased over the past decade with four approved oral …
sclerosis have substantially increased over the past decade with four approved oral …
[HTML][HTML] Ofatumumab versus teriflunomide in multiple sclerosis
Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry
CS Simonsen, HØ Flemmen, L Broch… - Frontiers in …, 2021 - frontiersin.org
Background: Moderate and high efficacy disease modifying therapies (DMTs) have a
profound effect on disease activity. The current treatment guidelines only recommend high …
profound effect on disease activity. The current treatment guidelines only recommend high …
Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis
I Roos, S Hughes, G McDonnell, CB Malpas… - JAMA …, 2023 - jamanetwork.com
Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B
cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared …
cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared …
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
Background SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute
respiratory distress syndrome (ARDS), which can cause significant mortality, leading to …
respiratory distress syndrome (ARDS), which can cause significant mortality, leading to …
Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis
Background and Objectives To evaluate the rate of return of disease activity after cessation
of multiple sclerosis (MS) disease-modifying therapy. Methods This was a retrospective …
of multiple sclerosis (MS) disease-modifying therapy. Methods This was a retrospective …
Dimethyl fumarate: a review in relapsing-remitting MS
HA Blair - Drugs, 2019 - Springer
Dimethyl fumarate (Tecfidera®) is approved for the treatment of relapsing forms of multiple
sclerosis (MS). Based on evidence from the clinical trial and real-world settings, dimethyl …
sclerosis (MS). Based on evidence from the clinical trial and real-world settings, dimethyl …
Early predictors of conversion to secondary progressive multiple sclerosis
M Barzegar, S Najdaghi, A Afshari-Safavi… - Multiple sclerosis and …, 2021 - Elsevier
Background: We conducted this study to estimated the time of conversion from relapsing-
remitting MS (RRMS) to SPMS and its early predictor factors. Methods: In this retrospective …
remitting MS (RRMS) to SPMS and its early predictor factors. Methods: In this retrospective …
Comparison of dimethyl fumarate vs fingolimod and rituximab vs natalizumab for treatment of multiple sclerosis
Importance As disease-modifying treatment options for multiple sclerosis increase,
comparisons of the options based on real-world evidence may guide clinical decision …
comparisons of the options based on real-world evidence may guide clinical decision …